How VKTX (Viking Therapeutics) Makes Money in 2025: A Deep-Dive With Income Statement

Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io

Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.

Understanding how a biotechnology innovator like VKTX Income Statement Overview makes money is essential for investors and anyone interested in the business of drug discovery and development. In this post, we break down VKTX's quarterly income statement (Q3 2025) using a Sankey chart to visualize the financial flows — what comes in, where it goes, and what's left as profit.

Quick VKTX Overview

VKTX Income Statement Overview operates as a clinical-stage biotechnology company focused on developing novel therapeutics for metabolic and endocrine disorders. Revenue comes primarily from milestone payments, licensing agreements, and collaboration income, as VKTX does not yet have commercialized products. The company’s business model is centered on advancing its pipeline of drug candidates through clinical trials, with the goal of eventual regulatory approval and commercialization.

Revenue Breakdown

• Total Revenue (Q3 2025): Not reported (VKTX reported no product revenue for the quarter; income is primarily from other sources)
  • No commercial product sales; revenue is typically from milestone or collaboration payments when present.
  • Growth is powered by progress in clinical development and strategic partnerships.

Gross Profit and Margins

• Gross Profit: Not reported (no product revenue in Q3 2025)
  • Cost of Revenue: Not reported (no cost of goods sold due to lack of commercial sales)
  • VKTX maintains negative gross margins as a pre-commercial biotech, reflecting its focus on R&D rather than revenue generation.
• Most costs come from research and development (R&D) expenses, which are essential for advancing the drug pipeline.

Operating Income and Expenses

• Operating Income: Not reported (operating loss expected due to high R&D and no product revenue)
• Operating Expenses: $98.6M (down 169.6% YoY)
  • R&D: $90.0M (+294.8% YoY, 0.0% of revenue) — VKTX’s investment is concentrated in advancing clinical trials for its lead drug candidates, including metabolic and liver disease therapies.
  • SG&A: $8.608M (-37.5% YoY, 0.0% of revenue) — Covers corporate operations, legal, and administrative functions.
  • VKTX continues to prioritize innovation and clinical progress while maintaining lean administrative operations.

Net Income

• Pre-Tax Income: Not reported (no pre-tax income due to operating losses)
• Income Tax: Not reported (no taxable income)
• Net Income: $90.8M (+264.0% YoY, 0.0% net margin)
• VKTX converts a significant portion of its non-operating income (such as milestone or other income) into net profit for the quarter, despite ongoing operating losses.

What Drives VKTX's Money Machine?

• Other Income: $90.8M in Q3 2025, representing the entirety of reported income for the quarter, likely from a milestone payment or similar non-recurring event.
• R&D Investment: $90.0M, reflecting VKTX’s commitment to advancing its clinical pipeline.
• Strategic Partnerships: VKTX’s financials are heavily influenced by collaboration agreements and milestone payments from partners.
• Future Growth Areas: Commercialization of lead drug candidates and expansion into new indications, though these have not yet generated recurring revenue.

Visualizing VKTX's Financial Flows

The Sankey chart below visualizes how each dollar flows from gross revenue (or other income), through costs and expenses, down to net income. This helps investors spot where value is created, what areas weigh on profits, and how efficiently the company operates.

• Most revenue flows into gross profit, with operating expenses (especially R&D) taking the largest chunk.
• Even after large investments in R&D, the $90.8M in other income drops directly to the bottom line for Q3 2025.

Key Takeaways

• VKTX's money comes overwhelmingly from milestone or other non-recurring income, not product sales.
• High R&D expenses and lack of commercial revenue are typical for a clinical-stage biotech, but strategic income events can result in positive net income.
• Heavy investment in clinical development, balanced by lean SG&A costs.
• Ongoing growth is driven by pipeline progress and potential future product launches.

Explore More Investment Opportunities

For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:

📌 50 Undervalued Stocks (Best) overall value plays for 2025
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)

🔍 Check out these stocks on the Value Sense platform for free!

FAQ About VKTX's Income Statement

1. What is the main source of VKTX's revenue in 2025?

VKTX generates over 100% of its reported income in Q3 2025 from "Other Income" $90.8M, likely a milestone or collaboration payment. There were no commercial product revenues in the quarter.

2. How profitable is VKTX in Q3 2025?

VKTX reported net income of $90.8M in Q3 2025, with a net margin of approximately 0.0% (as a percentage of revenue, since revenue is not reported), reflecting significant profitability for the quarter due to non-recurring income, despite ongoing operating losses.

3. What are the largest expense categories for VKTX?

The biggest expenses on VKTX's income statement are operating expenses, particularly Research & Development (R&D) at $90.0M in Q3 2025, as VKTX prioritizes clinical trial advancement and drug development.

4. Why does the R&D segment operate at a loss?

R&D, despite being the primary focus with $90.0M in expenses, does not generate direct revenue and posted an operating loss in Q3 2025. This is because VKTX aggressively invests in developing its drug pipeline, believing these will drive long-term growth—even if the segment is unprofitable today.

5. How does VKTX's effective tax rate compare to previous years?

VKTX's effective tax rate in Q3 2025 was not reported, as the company had no taxable income due to operating losses. This is consistent with prior periods for pre-commercial biotech firms, where tax rates are typically low or not meaningful due to net losses.